NCT02035605View on ClinicalTrials.gov

A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

January 20, 2014

Primary Completion Date

July 20, 2017

Study Completion Date

July 20, 2017

Conditions
Hemophilia AHemophilia B
Interventions
DRUG

ALN-AT3SC

Ascending doses of ALN-AT3SC by subcutaneous (sc) injection

DRUG

Sterile Normal Saline (0.9% NaCl)

Calculated volume to match active comparator

Trial Locations (14)

Unknown

Clinical Trial Site, Pittsburgh

Clinical Trial Site, Plovdiv

Clinical Trial Site, Sofia

Clinical Trial Site, Varna

Clinical Trial Site, Kirov

Clinical Trial Site, Moscow

Clinical Trial Site, Saint Petersburg

Clinical Trial Site, Sankt Gallen

Clinical Trial Site, Zurich

Clinical Trial Site, Glasgow

Clinical Trial Site, Manchester

Clinical Trial Site, Truro

NW3 2QG

Clinical Trial Site, London

SE1 1YR

Clinical Trial Site, London

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT02035605 - A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients | Biotech Hunter | Biotech Hunter